Tumor size, stage and grade alterations of urinary peptidome in RCC
Authors:
- Clizia ChinelloCCClizia Chinello
- Marta CazzanigaMCMarta Cazzaniga
- Gabriele De SioGSGabriele De Sio
- Andrew James SmithASAndrew James Smith
- Angelica GrassoAGAngelica Grasso
- Bernardo RoccoBRBernardo Rocco
- Stefano SignoriniSSStefano Signorini
- Marco GrassoMGMarco Grasso
- Silvano BosariSBSilvano Bosari
- Italo ZoppisIZItalo Zoppis
- Giancarlo MauriGMGiancarlo Mauri
- Fulvio MagniFMFulvio Magni
Open Access
- 20 October 2015
- journal article
- research article
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 13 (1) , 1-11
Abstract
Several promising biomarkers have been found for RCC, but none of them has been used in clinical practice for predicting tumour progression. The most widely used features for predicting tumour aggressiveness still remain the cancer stage, size and grade. Therefore, the aim of our study is to investigate the urinary peptidome to search and identify peptides whose concentrations in urine are linked to tumour growth measure and clinical data. A proteomic approach applied to ccRCC urinary peptidome (n = 117) based on prefractionation with activated magnetic beads followed by MALDI-TOF profiling was used. A systematic correlation study was performed on urinary peptide profiles obtained from MS analysis. Peptide identity was obtained by LC–ESI–MS/MS. Fifteen, twenty-six and five peptides showed a statistically significant alteration of their urinary concentration according to tumour size, pT and grade, respectively. Furthermore, 15 and 9 signals were observed to have urinary levels statistically modified in patients at different pT or grade values, even at very early stages. Among them, C1RL, A1AGx, ZAG2G, PGBM, MMP23, GP162, ADA19, G3P, RSPH3, DREB, NOTC2 SAFB2 and CC168 were identified. We identified several peptides whose urinary abundance varied according to tumour size, stage and grade. Among them, several play a possible role in tumorigenesis, progression and aggressiveness. These results could be a useful starting point for future studies aimed at verifying their possible use in the managements of RCC patients.Keywords
Funding Information
- Ministero dell’Istruzione, dell’Università e della Ricerca (IT) (RBRN07BMCT_11, FAR 2012-2014)
- Seventh Framework Programme (BE) (FP7-PEOPLE-2013-ITN-608332)
This publication has 50 references indexed in Scilit:
- Differential Expression of Prognostic Proteomic Markers in Primary Tumour, Venous Tumour Thrombus and Metastatic Renal Cell Cancer Tissue and Correlation with Patient OutcomePLOS ONE, 2013
- Survival and Impact of Clinical Prognostic Factors in Surgically Treated Metastatic Renal Cell CarcinomaEuropean Urology, 2013
- Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2012
- Comprehensive fluorogenic derivatization–liquid chromatography/tandem mass spectrometry proteomic analysis of colorectal cancer cell to identify biomarker candidateBiomedical Chromatography, 2012
- Decreased expression of zinc-alpha2-glycoprotein in hepatocellular carcinoma associates with poor prognosisJournal of Translational Medicine, 2012
- Analysis of cancer metabolism with high-throughput technologiesBMC Bioinformatics, 2011
- Significance of Heparanase in Cancer and InflammationCancer Microenvironment, 2011
- Stage-Related Alterations in Renal Cell Carcinoma – Comprehensive Quantitative Analysis by 2D-DIGE and Protein Network AnalysisPLOS ONE, 2011
- The Differentiation and Stress Response Factor XBP-1 Drives Multiple Myeloma PathogenesisCancer Cell, 2007
- ADAMs in cancer cell proliferation and progressionCancer Science, 2007